Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-03-03

Clinical Trial Update: Subconjunctival Bevacizumab Effect on Bleb Vascularity [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating subconjunctival bevacizumab to impact bleb vascularity and fibrosis after trabeculectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)

Snippet

Sponsor: Rabin Medical Center | Conditions: Bleb Vascularity, Bleb Fibrosis | Phase 2 | Status: UNKNOWN